Target Information

Target General Infomation
Target ID
T62005
Former ID
TTDR00244
Target Name
Integrin alpha-V/beta-3
Synonyms
Alpha v beta 3 integrin; Alpha(v)beta(3) Integrin; Integrin alpha-v beta-3; Integrin alphaVbeta3; Vitronectin Receptor
Target Type
Clinical Trial
Disease Melanoma [ICD9: 172; ICD10: C43]
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890]
Ocular disease [ICD10: H00-H59]
Prostate cancer [ICD9: 185; ICD10: C61]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
BioChemical Class
Integrin
UniProt ID
P06756||P05106
Drugs and Mode of Action
Drug(s) Cilengitide Drug Info Phase 3 Rheumatoid arthritis [522337], [541715]
Fluciclatide F-18 Drug Info Phase 2 Solid tumours [549142]
Intetumumab Drug Info Phase 2 Prostate cancer [522130]
AMEP Drug Info Phase 1 Melanoma [551212]
Vitaxin Drug Info Discontinued in Phase 2 Solid tumours [545816]
SB-267268 Drug Info Discontinued in Phase 1 Osteoporosis [547185]
SB-273005 Drug Info Discontinued in Phase 1 Osteoporosis [547112]
PS-388023 Drug Info Terminated Ocular disease [548165]
Modulator AMEP Drug Info
Cilengitide Drug Info
Fluciclatide F-18 Drug Info
Intetumumab Drug Info [531554]
PS-388023 Drug Info [556264]
SB-267268 Drug Info [528102]
SB-273005 Drug Info
Vitaxin Drug Info
Antagonist IS20I Drug Info [535641]
References
Ref 522130ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
Ref 522337ClinicalTrials.gov (NCT00689221) Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status. U.S. National Institutes of Health.
Ref 541715(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6597).
Ref 545816Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004890)
Ref 547112Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013133)
Ref 547185Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013716)
Ref 548165Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022665)
Ref 549142Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032798)
Ref 551212Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
Ref 528102SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
Ref 531554A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
Ref 535641IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery. 2003 Jan;52(1):177-85; discussion 185-6.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.